Introduction [11.6.1]
The introduction to the section highlights the increased risk of osteoporotic fractures following the menopause, coinciding with loss of ovarian function which leads to increased bone turnover and loss of bone density. A description of other clinical risk factors for fragility fractures is presented together with a list of alternative therapies to HRT for treatment of osteoporosis. It is noted that although some HRTs are licensed for osteoporosis prevention, none is licensed for osteoporosis treatment in the United Kingdom. ''The aim of the review was to identify whether HRT use modifies the risk of developing osteoporosis'' 1 [11.6.2] in postmenopausal women.
Review question [11.6.2]
The NICE guideline development group assessed the published literature addressing the effects of HRT on the risk of developing osteoporosis, focussing on different sites of fracture. It also assessed the effects of duration of use, timing of initiation following menopause onset, the effect of the different HRT treatments and of time since discontinuation of treatment.
Description of included studies [11.6.3]
Twenty randomised control trials (RCTs) were included in the review, the majority being from the United States. Half of these studies were of estrogen plus progestogen, five were estrogen alone, four included both estrogen alone and combined HRT and one also included a progestogen-alone arm. Sample sizes of the RCTs varied widely, ranging from 36 to 16,608 cases. Twenty-one comparative cohort studies which compared HRT with no treatment were included. Sample sizes of the cohort studies also varied widely, ranging from 157 to 170,852 cases. The age at enrolment was mainly between 40 and 79 years.
Evidence statements [11.6.5]
The evidence from RCTs in women currently using HRT showed a significant reduction in risk of any fracture compared with women not using HRT. Significant reductions were seen in non-vertebral fractures, but not vertebral fractures, in several RCTs. However, contradictory findings came from a meta-analysis of RCTs which showed significant reductions in risk of both vertebral and non-vertebral fractures with use of estrogen plus progestogen. The reduction in fracture risk appears to become apparent after more than two years therapy. Age at initiation of HRT appeared to influence the risk reduction with older women showing benefit, but findings were somewhat inconsistent. The quality of evidence from all these studies was regarded as moderate to very low by the development group.
The evidence from comparative cohort studies showed reduced risk of any and all fractures with current HRT use compared with non-use, whether previous or never use. It was stated that subgroup analyses showed that fracture risk reduction was independent of duration of HRT use, but confusingly this finding was stated to come from RCTs! Subgroup analyses from cohort studies on duration of HRT use did not produce clear results. The presentation by the group on the effect of timing of HRT discontinuation suggested that fracture risk reduction disappeared in under 5 years.
Consideration of clinical
benefits and harms [11.6.7.2
]
The evidence summarised in the guideline both from RCTs and observational data showed a consistent reduction in risk of any fragility fracture, including hip fracture in the cohort studies, with current HRT risk, both for estrogen alone and estrogen-progestogen therapy. Duration of use did not affect risk reduction in the RCTs, but hip fracture reduction was only seen with HRT duration above 10 years in the observational studies. Studies did not suggest any effect of age at initiation of HRT on fracture risk. The group stated that fracture protection was preserved after HRT discontinuation in the cohort studies, although this seems to be at odds with their evidence statements [11.6.5] and The group concluded that that the evidence for fracture reduction with HRT was robust and this protection persisted after HRT discontinuation. Age and duration of treatment did not influence these conclusions.
Recommendations [1.3] [11.6.8]
The guideline states the following recommendations:
. ''Give women advice on bone health and discuss these issues at review appointments'' 1 [11.6.8.50]. . Explain that the fracture risk for women around age of menopause is low but varies between individuals. . Explain that the risk of fragility fracture is decreased whilst taking HRT. This ''benefit is maintained during treatment but decreases once treatment stops . . . but may continue for longer in women who take HRT for longer'' 1 [11.6.8.52].
They suggest using Table 4 [11.6.8] to explain these absolute risks to women. As with other tables in the entire document, they give the reference for the numbers in the table as Appendix M [15] but this does not indicate which studies were used to give these numbers.
Comment
The group has clearly demonstrated the major benefits of HRT for fracture prevention. The evidence is robust and shows that HRT is also effective for osteoporosis treatment as well as prevention. 2 No mention is made of any effect of estrogen dose on fracture risk. Studies of bone density have shown a dose response effect, with higher doses having a greater effect, 3 but there are few data on dose and fracture risk. The Million Women Study showed no obvious effect of HRT dose on fracture reduction, even showing a non-significant greater reduction with 1 mg oral oestradiol compared with 2 mg 4 which calls into question the validity of these findings.
There is no comment from the group on the current recommendation of the Medicines & Healthcare products Regulatory Agency (MHRA), which persists with the original recommendation in 2003 from the UK Committee on Safety of Medicines (CSM), that HRT should not be regarded as first-line therapy for prevention of osteoporosis. This recommendation has been vigorously challenged, 5 yet has not been updated or modified for over 8 years. In the light of current evidence, the MHRA standpoint is unjustified and unjustifiable. Sadly, it is not within the remit of the group to advise changes to the regulatory authorities recommendations.
